Home
Pain Therapeutics
20 May - 21 May 2013
Pain Therapeutics

Pain is the primary reason that patients seek medical care and the pain therapeutics industry is currently under financial strain. With this in mind, SAE Media Group are very pleased to present our 13th annual Pain Therapeutics conference which will highlight improvements in R&D methods and certifying that drugs being put forward for clinical trials are given the best chance to succeed. The conference will take place on the 20th and 21st of May 2013 and will provide a unique platform to engage with KOLs and esteemed academia in the field of pain therapeutics. With a spotlight on areas such as: current targets for analgesic development, personalised medicine, the cannabinoid approach , imaging modalities, experimental models in early phase clinical development & improving clinical trial success rates, Pain Therapeutics 2013 promises to be a truly unmissable event!

FEATURED SPEAKERS

Anthony Kenneth Peter Jones

Anthony Kenneth Peter Jones

Professor of Neuro-Rheumatology, University of Manchester
Dave Shelton

Dave Shelton

Senior Director, Pfizer Global Research & Development
Huw Rees

Huw Rees

Senior Principal Scientist, Pfizer
Iain Chessell

Iain Chessell

VP R&D Neuroscience Innovative Medicines, MedImmune
Narender Gavva

Narender Gavva

Scientific Director, Amgen

Anthony Kenneth Peter Jones

Professor of Neuro-Rheumatology, University of Manchester
Anthony Kenneth Peter Jones

Dave Shelton

Senior Director, Pfizer Global Research & Development
Dave Shelton

David Walsh

Director of the ARC National Pain Centre, University of Nottingham
David Walsh

David Yeomans

Director of Pain Research, Stanford University School Of Medicine
David Yeomans

Fiona Boissonade

Head of Neuroscience Research Group, The University Of Sheffield
Fiona Boissonade

Gary Patou

Chief Medical Officer, Pacira Pharmaceuticals Inc
Gary Patou

Huw Rees

Senior Principal Scientist, Pfizer
Huw Rees

Iain Chessell

VP R&D Neuroscience Innovative Medicines, MedImmune
Iain Chessell

John Connell

Vice President Clinical Pharmacodynamics, ICON Development Solutions
John Connell

Lars Arendt-Nielsen

Director, Aalborg University
Lars Arendt-Nielsen

Narender Gavva

Scientific Director, Amgen
Narender Gavva

Paul Karila

Head of Discovery Services, Cellectricon
Paul Karila

Peter McNaughton

Head of Pharmacology Department, Cambridge University
Peter McNaughton

Sigal Meilin

Scientific Director, MD Biosciences
Sigal Meilin

Steve Harrison

Vice President, Research Biology, Nektar Therapeutics
Steve  Harrison

Thomas Christoph

Senior Director, Head of Pain Pharmacology, Grunenthal Gmb H
Thomas Christoph

Valerie Morisset

Head of Electrophysiology, Convergence Pharmaceuticals
Valerie Morisset

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Narender Gavva

Narender Gavva, Scientific Director, Amgen

clock

9:10

Use of DNA directed RNA interference as a new approach to long term pain therapy

David Yeomans

David Yeomans, Director of Pain Research, Stanford University School Of Medicine

  • The advantages of an RNA interference approach to pain therapy
  • Rationale for target selection
  • Progress to date and challenges to overcome
  • clock

    9:50

    Novel readouts for the analysis of spontaneous pain in animals

    Thomas Christoph

    Thomas Christoph, Senior Director, Head of Pain Pharmacology, Grunenthal Gmb H

  • How do evoked methods compare with non-evoked?
  • Are innate responses of animals suitable measures for chronic pain?
  • Are different pain indications amenable to similar readouts?
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Identification of modulators of chronic pain in native sensory neurons using a novel phenotypic assay

    Paul Karila

    Paul Karila, Head of Discovery Services, Cellectricon

  • Methodologies for detection of changes in neuronal excitability
  • Phenotypic approach enables detection of compounds acting along the peripheral sensitization pathway on previously unknown targets
  • Presentation of validation data and case study
  • Progress to date and challenges to overcome
  • clock

    11:40

    Optimising the context of medical treatments for arthritis pain

    David Walsh

    David Walsh, Director of the ARC National Pain Centre, University of Nottingham

  • The context within which treatments are given
  • Placebo and nocebo
  • The place of medical analgesia in patient pathways for chronic arthritis pain.
  • The person-specific context; mechanistic, diagnostic and severity-based approaches to stratified care
  • clock

    12:20

    Exploring the use of animal models to study pain pathways

    Huw Rees

    Huw Rees, Senior Principal Scientist, Pfizer

  • Mechanistic studies; examining the role of NaV1.7 in rats and mice
  • Addressing bias in preclinical studies; being more clinical in experimental design
  • Future directions; re-evaluating the role of wide dynamic range neurones in models of nerve injury
  • clock

    13:00

    Networking Lunch

    clock

    14:20

    Novel pain therapeutics with low CNS side effects

    Steve  Harrison

    Steve Harrison, Vice President, Research Biology, Nektar Therapeutics

  • Use of polymer conjugation technology to develop novel opioids with intrinsically low abuse liability
  • Analgesics for neuropathic pain with reduced CNS side effects
  • The future potential of polymer conjugation technology in pain therapy
  • clock

    15:00

    The use of biologic therapies in the treatment of pain - A CASE STUDY of anti-NGFs

    Iain Chessell

    Iain Chessell, VP R&D Neuroscience Innovative Medicines, MedImmune

  • Why consider biologic therapies for pain: pros and cons
  • Considerations around target selection
  • Case study: anti-NGF therapies
  • Translation from man to animal to man
  • Next steps for novel biologic therapies
  • clock

    15:40

    Afternoon Tea

    clock

    16:00

    A novel target for chronic migraine therapy: clinical demonstration of nasal oxytocin efficacy and safety

    David Yeomans

    David Yeomans, Director of Pain Research, Stanford University School Of Medicine

  • Oxytocin receptors are present on trigeminal pain-sensing neurons and are upregulated by painful inflammation
  • Nasal application of oxytocin concentrates the drug in the trigeminal system
  • Results of a 40 patient chronic migraine trial
  • clock

    16:40

    Panel Discussion - Pain therapeutics: where are we, and what is the potential for the future?

    Narender Gavva

    Narender Gavva, Scientific Director, Amgen

    clock

    17:10

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Dave Shelton

    Dave Shelton, Senior Director, Pfizer Global Research & Development

    clock

    9:10

    Translational mechanistic pain biomarkers

    Lars Arendt-Nielsen

    Lars Arendt-Nielsen, Director, Aalborg University

  • Phase I and II proof-of-concept
  • Pharmacodynamics &Mechanism based drug profiling
  • Healthy volunteer studies
  • Proof-of-mechanism
  • Translation of animal data into pain patients
  • clock

    9:50

    Human tissues as a translational tool in pain research and target identification

    Fiona Boissonade

    Fiona Boissonade, Head of Neuroscience Research Group, The University Of Sheffield

  • Studies of neuropathic pain
  • Studies of inflammatory pain
  • Correlation with pre-clinical models
  • clock

    10:30

    Morning Coffee

    clock

    10:50

    Imaging the common brain substrates of chronic pain- it’s all anticipation

    Anthony Kenneth Peter Jones

    Anthony Kenneth Peter Jones, Professor of Neuro-Rheumatology, University of Manchester

  • Recent research to suggest that fundamental changes in physiology of chronic pain sufferers may alter their PD compared to experimental models of healthy patients
  • Can this research help to illuminate better ways at predicting drug PD in patients?
  • How do these physiological changes relate to pain?
  • clock

    11:30

    Translation of Preclinical Pain Models - what is missing?

    Sigal Meilin

    Sigal Meilin, Scientific Director, MD Biosciences

  • Current approach to developing pain therapies relies on mechanistic approach, however neuropathic pain in humans is rarely caused by a simple event
  • Commonly pain studies ignore the fact that pain is a complex process
  • New approach needs to consider relevant species, clinically relevant measures and understanding the emotional, learning and memory aspect of pain
  • clock

    11:55

    Novel targets in inflammatory and neuropathic pain

  • Inflammatory and neuropathic pain poorly treated by current analgesics – poor efficacy and many side effects
  • Recent work in the McNaughton lab has identified the HCN2 ion channel and the AKAP79 scaffolding protein as potential targets
  • Progress towards developing selective drugs
  • Peter McNaughton

    Peter McNaughton, Head of Pharmacology Department, Cambridge University

    clock

    12:35

    Opiate development: how efficacy, side-effect profiling, and target engagement can be rapidly and cost-effectively established in Phase I

    John Connell

    John Connell, Vice President Clinical Pharmacodynamics, ICON Development Solutions

  • Can human pain models indicate efficacy in patients?
  • Role of PK-PD modeling and simulation in guiding dose selection for patient trials
  • What side effects of opiates can reasonably be explored in a healthy volunteer
  • Impact of FDA guidelines on opiate-abuse on early phase opiate development
  • clock

    13:00

    Networking Lunch

    clock

    14:00

    Challenges in analgesic drug discovery

    Narender Gavva

    Narender Gavva, Scientific Director, Amgen

  • Emphasis is on preclinical discovery
  • Potential false-positive hotspots
  • Best practices for target selection criteria
  • clock

    14:40

    The use of anti-NGF agents in pain

    Dave Shelton

    Dave Shelton, Senior Director, Pfizer Global Research & Development

  • Novel approach to treating pain
  • anti-NGF in clinical trials
  • Challenges faced
  • Future of anti-NGF agents
  • clock

    15:20

    Afternoon Tea

    clock

    15:40

    CASE STUDY: Phase 3 and phase 4 trial experience with Exparel for prolonged post operative analgesia

    Gary Patou

    Gary Patou, Chief Medical Officer, Pacira Pharmaceuticals Inc

  • Overview of Exparel and its mode of action
  • Discussion of the trial methodology used for drug approval
  • Phase 4 demonstration of health outcomes
  • clock

    16:20

    CASE STUDY: Focus on Nav1.7 blockers for chronic pain

    Valerie Morisset

    Valerie Morisset, Head of Electrophysiology, Convergence Pharmaceuticals

  • Overview of Nav1.7 blockers field
  • Preclinical properties of Nav1.7 blocker CNV1014802 / comparison with anti convulsants used in the clinic
  • Clinical development
  • clock

    17:00

    Chairman’s Closing Remarks and Close of Day Two


    Senior Director, Head of Pain Pharmacology
    Grunenthal Gmb H
    Director of the ARC National Pain Centre
    University of Nottingham
    Senior Principal Scientist
    Pfizer
    Scientific Director
    MD Biosciences
    Senior Director
    Pfizer Global Research & Development
    Vice President, Research Biology
    Nektar Therapeutics
    Director of Pain Research
    Stanford University School Of Medicine
    VP R&D Neuroscience Innovative Medicines
    MedImmune
    Director
    Aalborg University
    Head of Neuroscience Research Group
    The University Of Sheffield
    Professor of Neuro-Rheumatology
    University of Manchester
    Head of Pharmacology Department
    Cambridge University
    Scientific Director
    Amgen
    Vice President Clinical Pharmacodynamics
    ICON Development Solutions
    Head of Electrophysiology
    Convergence Pharmaceuticals
    Chief Medical Officer
    Pacira Pharmaceuticals Inc
    Head of Discovery Services
    Cellectricon

    Workshops

    Human Pain Models - Lost in Translation?
    Workshop

    Human Pain Models - Lost in Translation?

    Copthorne Tara Hotel
    22 May 2013
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.